key: cord-0787757-othoz5e2 authors: Acharya, Arpan; Pandey, Kabita; Thurman, Michellie; Challagundala, Kishore B.; Vann, Kendra R.; Kutateladze, Tatiana G.; Morales, Guillermo A; Durden, Donald L.; Byrareddy, Siddappa N. title: Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor date: 2021-03-05 journal: bioRxiv DOI: 10.1101/2021.03.02.433604 sha: dba4796a9aaaf599813fa94e28a5b6a4157f54b1 doc_id: 787757 cord_uid: othoz5e2 Pathogenic viruses like SARS-CoV-2 and HIV hijack the host molecular machinery to establish infection and survival in infected cells. This has led the scientific community to explore the molecular mechanisms by which SARS-CoV-2 infects host cells, establishes productive infection, and causes life-threatening pathophysiology. Very few targeted therapeutics for COVID-19 currently exist, such as remdesivir. Recently, a proteomic approach explored the interactions of 26 of 29 SARS-CoV-2 proteins with cellular targets in human cells and identified 67 interactions as potential targets for drug development. Two of the critical targets, the bromodomain and extra-terminal domain proteins (BETs): BRD2/BRD4 and mTOR, are inhibited by the dual inhibitory small molecule SF2523 at nanomolar potency. SF2523 is the only known mTOR PI3K-α/(BRD2/BRD4) inhibitor with potential to block two orthogonal pathways necessary for SARS-CoV-2 pathogenesis in human cells. Our results demonstrate that SF2523 effectively blocks SARS-CoV-2 replication in lung bronchial epithelial cells in vitro, showing an IC50 value of 1.5 µM, comparable to IC50 value of remdesivir (1.1 µM). Further, we demonstrated that the combination of doses of SF2523 and remdesivir is highly synergistic: it allows for the reduction of doses of SF2523 and remdesivir by 25-fold and 4-fold, respectively, to achieve the same potency observed for a single inhibitor. Because SF2523 inhibits two SARS-CoV-2 driven pathogenesis mechanisms involving BRD2/BRD4 and mTOR signaling, our data suggest that SF2523 alone or in combination with remdesivir could be a novel and efficient therapeutic strategy to block SARS-CoV-2 infection and hence be beneficial in preventing severe COVID-19 disease evolution. One Sentence Summary Evidence of in silico designed chemotype (SF2523) targeting PI3K-α/mTOR/BRD4 inhibits SARS-CoV-2 infection and is highly synergistic with remdesivir. interactions and targets for drug development. By molecular pathway analysis, they 118 demonstrated an interaction of BRD2/BRD4 with E protein of SARS-CoV-2. In another study 119 Tian et al. using CRISPRi screening shown that BRD2 inhibition down regulate the ACE2 120 expression which block the entry of SARS-CoV-2 within host cells as well as control 121 hyperactive immune response in COVID-19 patients through down regulations of ISGs (30). 122 Therefore, they proposed BRD2 as a potential target for development of therapeutics against 137 In a recent study using proteomic analysis, Gordon et al. (29) identified 67 host factors that 138 interact with SARS-CoV-2 proteins and represent potential drug development targets. Two of the 139 potential host targets identified, BETs BRD2/BRD4 and mTOR, are inhibited by SF2523. µM and remdesivir has an IC50 of 1.03 µM ( Fig. 2C and 2D ). SARS-CoV-2 replication kinetics 164 48 hrs post-infection in SF2523 and remdesivir treated UNCN1T and Vero-STAT1 knockout 165 cells are described in Fig. S1A and Fig. S1B , respectively. SF2523 and remdesivir have an IC50 166 value of 1.58 µM and 2.75 µM in UNCN1T cells (Fig. S1C) and IC50 of 3.22 µM and 0.76 µM 167 in Vero-STAT1 knockout cells (Fig. S1D) , respectively. (Fig 4D) . Synergy maps highlight synergistic and 204 antagonistic dose regions in red and green colors, respectively. Although there is no defined 205 threshold, drug combinations with a synergy scores above -10 is considered likely antagonistic, 206 and a score between -10 to 10 is deemed a possible additive. Any score above 10 is considered of these domains (Fig. 6) . However, the subsequent addition of SF2523 to the NMR samples of 232 BD1 and BD2 led to large resonance changes, indicating robust binding, and no binding of 233 SF2523 was detected to the ET domain of BRD4. 291 To characterize the molecular basis for SF2523 mediated inhibition of SARS-CoV-2 replication 292 and confirm the synergistic combination of this compound with remdesivir in vitro, we used 293 NMR to look at the capacity of these two chemotypes to interact with BRD4-BD1, BRD4-BD2, 294 and BRD4-ET domains. Consistent with the substantial synergy noted with the two agents, 295 remdesivir did not bind to BRD4; however, SF2523 binds to both BD1 and BD2 but not the 296 extra-terminal (ET) domain of BRD4, supporting differential molecular pathways targeted by 297 these chemically distinct chemotypes. BRD2/BRD4 are epigenetic factors whose two N-298 terminal bromodomains (BDs) bind with acetylated histones and regulate several proteins (52). Several observations related to Gordon et al. (29) reporting that BRD4 binds to the SARS-CoV-2 300 14 E protein include: 1) the E protein forms a homopentameric cation-selective channel which is 301 required for viral budding and release from cells, 2) the E protein is a 72-residue viroporin Our initial efforts to screen the efficacy of SF2523 monotherapy and combinational therapy 323 against SARS-CoV-2 in the 2D-cellular model is an essential step for initial screening of drug 324 like compounds before initiation of pre-clinical studies and commonly used to explore the 325 molecular mechanism of action. Our future studies will reveal their efficacy in pre-clinical 326 animal models of COVID-19. Its synergistic effect will result in a favorable shift in the plasma 327 Cmax/EC90 ratio. Ongoing structural studies to elucidate the interaction of SF2523 with host 328 factors and viral targets will clarify mechanisms of efficacy, and potential resistance as the virus were purified from the cleared lysate using glutathione Sepharose 4B beads and the GST tag was 377 cleaved with PreScission or thrombin protease. The protein was purified using a S100 column 378 (GE Healthcare) equilibrated in 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP. BD1 SARS-CoV-2 isolate USA-WI1/2020 (BEI; cat# NR-52384) was procured from BEI and 408 passaged in Vero-STAT1 knockout cells. The viral titer was determined using plaque assay (60). In brief, Vero E6 cells were seeded in 6-well plates. After 24 hrs, cells were washed with sterile The epidemiology and pathogenesis of coronavirus disease 475 (COVID-19) outbreak New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology Dysregulation of Cell 480 Signaling by SARS-CoV-2 Characterization of spike 483 22 glycoprotein of SARS-CoV-2 on virus entry and its immune Tumor markers as an entry for SARS-CoV-2 infection? Neuropilin-1 facilitates SARS-CoV-2 cell entry 492 and infectivity Neuropilin-1 is a host factor for SARS-CoV-2 497 infection SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 501 Altan-Bonnet, N. Altan-Bonnet, beta-Coronaviruses Use Remdesivir as a possible therapeutic 552 option for the COVID-19 Remdesivir for the Treatment of Covid-19 -Final 560 Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial 574 Results In vitro evaluation of antiviral activity of single and combined 577 repurposable drugs against SARS-CoV-2 A 596 SARS-CoV-2 protein interaction map reveals targets for drug repurposing BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing 602 transcription of the host cell receptor ACE2. bioRxiv Theoretical basis, experimental design, and computerized simulation of 604 synergism and antagonism in drug combination studies Derivation and properties of Michaelis-Menten type and Hill type equations 607 for reference ligands Quantitative analysis of dose-effect relationships: the combined 609 effects of multiple drugs or enzyme inhibitors A Review of Its Discovery and Development Leading to Emergency Use 612 Authorization for Treatment of COVID-19 Dual-activity PI3K-BRD4 inhibitor for the orthogonal 615 inhibition of MYC to block tumor growth and metastasis Dual Kinase-Bromodomain Inhibitors in Anticancer Drug 618 Discovery: A Structural and Pharmacological Perspective SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer Dual inhibition of 625 BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno pyran-7-ones designed as next generation PI3K inhibitors AutoDock Vina: improving the speed and accuracy of docking with 632 a new scoring function, efficient optimization, and multithreading rDock: a fast, versatile and open source 636 program for docking ligands to proteins and nucleic acids Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain 640 of BRD4 Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a 644 Nonhuman Primate Model of Common Marmoset Medical treatment of viral 646 pneumonia including SARS in immunocompetent adult Temporal profiles of viral load in posterior oropharyngeal saliva 651 samples and serum antibody responses during infection by SARS-CoV-2: an observational 652 cohort study Antiviral combinations for severe influenza Efficacy of Clarithromycin-Naproxen Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial Accelerating Clinical Evaluation 664 of Repurposed Combination Therapies for COVID-19 Triple combination of interferon beta-672 lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with 673 COVID-19: an open-label, randomised, phase 2 trial Safety and efficacy of antiviral combination therapy in symptomatic patients of 676 Covid-19 infection -a randomised controlled trial (SEV-COVID Trial): A structured 677 summary of a study protocol for a randomized controlled trial Safety profile of the antiviral drug remdesivir: An 679 update Structure-guided drug design Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain 686 in lipid bilayers Mutational insights into the envelope protein of SARS-CoV-2 The BET family in immunity and disease Rapamycin as a potential repurpose drug candidate for the 693 treatment of COVID-19 Middle East Respiratory Syndrome and Severe Acute Respiratory 696 Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies 699 Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses 700 HIV-1 replication The Protein Data Bank Two Detailed Plaque Assay Protocols 704 for the Quantification of Infectious SARS-CoV-2 Drug combination studies and their synergy quantification using the Chou-707 Talalay method SynergyFinder 2.0: visual analytics of multi-drug 709 combination synergies Acknowledgements: We acknowledge the UNMC BSL-3 core facility for allowing us to 711 perform all in vitro experiments involving SARS-CoV-2. 'The University of Core Facility is administrated through the Office of the Vice Chancellor for 713 Research and supported by the Nebraska Research Initiative (NRI) NIH: (a) SARS-Related Coronavirus 2, Isolate USA-WI1/2020 Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related 717 Coronavirus 2, Isolate USA-WA1/2020, NR 52347 Funding: This work is partially supported by National Institute of Allergy and Infectious 719 Weese New Frontiers in Medical Research Fund to SNB and NIH grants HL151334 and 721 CA252707 to T GAM 729 Writing -review & editing Competing interests: DLD and GMA declare financial interest in SF2523 via their holding in 731 SignalRx Pharmaceuticals Data and materials availability: All data related with this study are presented in the manuscript Predicted binding (docking) of SF2523 in PI3K-a catalytic domain (upper panel) and 754 observed binding in crystal structure of SF2523 bound to BRD4-BD1 acetyl lysine binding site 755 (1.8 Angstroms resolution) (bottom panel) SARS-CoV-2 viral loads and dose-response curve in SF2523 and remdesivir treated 760 and SARS-CoV-2 infected UNCN1T cells and Vero-STAT1 knockout cells. (A & B) Real-761 time quantitative PCR analysis of SARS-CoV-2 genome equivalent per ml of culture supernatant 762 after 24 hrs post-infection in SF2523 (in blue) and remdesivir STAT1 knockout cells with indicated drug concentrations, respectively. (C & D) SF2523 (in blue) and remdesivir (in green) dose response curve by percentage inhibition of 765 SARS-CoV-2 replication 24 hrs post infection in UNCN1T cells and Vero-STAT1 knockout 766 cells with indicated drug concentrations, respectively Dose-response curve for single and combination of SF2523 and remdesivir in SARS-771 CoV-2 infected UNCN1T cells and Vero-STAT1 knockout cells 24 hrs post infection and 773 remdesivir with a fixed dose combination of SF2523 (0.1 µM) (red: IC50 = 0.625) by percentage 774 inhibition of SARS-CoV-2 replication 24 hrs post infection in UNCN1T cells; (B) Dose response 775 curve of remdesivir CoV-2 replication 24 hrs post infection (IC50 = 1.02 µM) in Vero-STAT1 knockout cells combinations with a synergy scores above -10 is considered likely antagonistic, score between -810 10 to 10 is considered likely additive and score above 10 is considered synergistic. no defined threshold, for drug combinations with a synergy scores above -10 is considered likely 837 antagonistic, score between -10 to 10 is considered likely additive and score above 10 is 838 considered synergistic.